Final height attainment in girls and boys with insulin-dependent diabetes mellitus

G. d'Annunzio, L. Cortona, L. Vitali, P. Pessino, R. Lorini

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

We compared final height to height at diagnosis (expressed as a standard deviation score, SDS), predicted adult height (according to the Bayley and Pinneau method) and target genetic height (expressed as mean parental height in cm, +6.5 for males and -6.5 for females) in 37 patients (15 males, 22 females) with insulin-dependent diabetes mellitus (IDDM), aged 20.6 ± 3.3 years (16.6-27), with 11.8 ± 3.7 years (5.2-19.2) mean duration of disease. In the 22 females, final height (162.4 ± 5.7 cm; range, 150-174 cm) was higher than predicted (161.5 ± 7.8 cm; range, 146-176.2 cm) and target genetic height (159.7 ±3.8 cm; range, 152.8-167.3 cm), although not significantly. Female patients showed a positive correlation between final height and both predicted (P <0.05) and target genetic height (P <0.005). No difference was observed in final height between patients diagnosed in the prepubertal or pubertal phase (162.2 ± 4.6 cm vs. 163.4 ± 6.2 cm; P-value n.s.). In the 15 males, final height (173.4 ± 4.4 cm; range, 166.5 ± 181 cm), lower than predicted (175.4 ± 4.9 cm; range, 166-183 cm), was higher than target genetic height (169.9 ± 4.8 cm; range, 162.4-177 cm) (P <0.05). Male patients showed a positive correlation between final height and target genetic height (P <0.05). No difference was found in final height between patients diagnosed in the prepubertal or pubertal phase (173.6 ± 3.5 cm vs. 172.7 ± 5.5 cm; P-value n.s.). No correlation was found between final height and age at onset, duration of disease, insulin requirement, or degree of metabolic control. Taking into account all patients, diabetes did not influence final height, which was higher than target genetic height. Only in 5 out of 37 patients with poor metabolic control was the final height lower than target genetic height.

Original languageEnglish
Pages (from-to)187-193
Number of pages7
JournalDiabetes Research and Clinical Practice
Volume24
Issue number3
DOIs
Publication statusPublished - 1994

Fingerprint

Type 1 Diabetes Mellitus
Age of Onset
Insulin

Keywords

  • Final height
  • Growth
  • Type 1 diabetes

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Final height attainment in girls and boys with insulin-dependent diabetes mellitus. / d'Annunzio, G.; Cortona, L.; Vitali, L.; Pessino, P.; Lorini, R.

In: Diabetes Research and Clinical Practice, Vol. 24, No. 3, 1994, p. 187-193.

Research output: Contribution to journalArticle

d'Annunzio, G. ; Cortona, L. ; Vitali, L. ; Pessino, P. ; Lorini, R. / Final height attainment in girls and boys with insulin-dependent diabetes mellitus. In: Diabetes Research and Clinical Practice. 1994 ; Vol. 24, No. 3. pp. 187-193.
@article{670d681379864b63a22a2eab59d884f6,
title = "Final height attainment in girls and boys with insulin-dependent diabetes mellitus",
abstract = "We compared final height to height at diagnosis (expressed as a standard deviation score, SDS), predicted adult height (according to the Bayley and Pinneau method) and target genetic height (expressed as mean parental height in cm, +6.5 for males and -6.5 for females) in 37 patients (15 males, 22 females) with insulin-dependent diabetes mellitus (IDDM), aged 20.6 ± 3.3 years (16.6-27), with 11.8 ± 3.7 years (5.2-19.2) mean duration of disease. In the 22 females, final height (162.4 ± 5.7 cm; range, 150-174 cm) was higher than predicted (161.5 ± 7.8 cm; range, 146-176.2 cm) and target genetic height (159.7 ±3.8 cm; range, 152.8-167.3 cm), although not significantly. Female patients showed a positive correlation between final height and both predicted (P <0.05) and target genetic height (P <0.005). No difference was observed in final height between patients diagnosed in the prepubertal or pubertal phase (162.2 ± 4.6 cm vs. 163.4 ± 6.2 cm; P-value n.s.). In the 15 males, final height (173.4 ± 4.4 cm; range, 166.5 ± 181 cm), lower than predicted (175.4 ± 4.9 cm; range, 166-183 cm), was higher than target genetic height (169.9 ± 4.8 cm; range, 162.4-177 cm) (P <0.05). Male patients showed a positive correlation between final height and target genetic height (P <0.05). No difference was found in final height between patients diagnosed in the prepubertal or pubertal phase (173.6 ± 3.5 cm vs. 172.7 ± 5.5 cm; P-value n.s.). No correlation was found between final height and age at onset, duration of disease, insulin requirement, or degree of metabolic control. Taking into account all patients, diabetes did not influence final height, which was higher than target genetic height. Only in 5 out of 37 patients with poor metabolic control was the final height lower than target genetic height.",
keywords = "Final height, Growth, Type 1 diabetes",
author = "G. d'Annunzio and L. Cortona and L. Vitali and P. Pessino and R. Lorini",
year = "1994",
doi = "10.1016/0168-8227(94)90115-5",
language = "English",
volume = "24",
pages = "187--193",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Final height attainment in girls and boys with insulin-dependent diabetes mellitus

AU - d'Annunzio, G.

AU - Cortona, L.

AU - Vitali, L.

AU - Pessino, P.

AU - Lorini, R.

PY - 1994

Y1 - 1994

N2 - We compared final height to height at diagnosis (expressed as a standard deviation score, SDS), predicted adult height (according to the Bayley and Pinneau method) and target genetic height (expressed as mean parental height in cm, +6.5 for males and -6.5 for females) in 37 patients (15 males, 22 females) with insulin-dependent diabetes mellitus (IDDM), aged 20.6 ± 3.3 years (16.6-27), with 11.8 ± 3.7 years (5.2-19.2) mean duration of disease. In the 22 females, final height (162.4 ± 5.7 cm; range, 150-174 cm) was higher than predicted (161.5 ± 7.8 cm; range, 146-176.2 cm) and target genetic height (159.7 ±3.8 cm; range, 152.8-167.3 cm), although not significantly. Female patients showed a positive correlation between final height and both predicted (P <0.05) and target genetic height (P <0.005). No difference was observed in final height between patients diagnosed in the prepubertal or pubertal phase (162.2 ± 4.6 cm vs. 163.4 ± 6.2 cm; P-value n.s.). In the 15 males, final height (173.4 ± 4.4 cm; range, 166.5 ± 181 cm), lower than predicted (175.4 ± 4.9 cm; range, 166-183 cm), was higher than target genetic height (169.9 ± 4.8 cm; range, 162.4-177 cm) (P <0.05). Male patients showed a positive correlation between final height and target genetic height (P <0.05). No difference was found in final height between patients diagnosed in the prepubertal or pubertal phase (173.6 ± 3.5 cm vs. 172.7 ± 5.5 cm; P-value n.s.). No correlation was found between final height and age at onset, duration of disease, insulin requirement, or degree of metabolic control. Taking into account all patients, diabetes did not influence final height, which was higher than target genetic height. Only in 5 out of 37 patients with poor metabolic control was the final height lower than target genetic height.

AB - We compared final height to height at diagnosis (expressed as a standard deviation score, SDS), predicted adult height (according to the Bayley and Pinneau method) and target genetic height (expressed as mean parental height in cm, +6.5 for males and -6.5 for females) in 37 patients (15 males, 22 females) with insulin-dependent diabetes mellitus (IDDM), aged 20.6 ± 3.3 years (16.6-27), with 11.8 ± 3.7 years (5.2-19.2) mean duration of disease. In the 22 females, final height (162.4 ± 5.7 cm; range, 150-174 cm) was higher than predicted (161.5 ± 7.8 cm; range, 146-176.2 cm) and target genetic height (159.7 ±3.8 cm; range, 152.8-167.3 cm), although not significantly. Female patients showed a positive correlation between final height and both predicted (P <0.05) and target genetic height (P <0.005). No difference was observed in final height between patients diagnosed in the prepubertal or pubertal phase (162.2 ± 4.6 cm vs. 163.4 ± 6.2 cm; P-value n.s.). In the 15 males, final height (173.4 ± 4.4 cm; range, 166.5 ± 181 cm), lower than predicted (175.4 ± 4.9 cm; range, 166-183 cm), was higher than target genetic height (169.9 ± 4.8 cm; range, 162.4-177 cm) (P <0.05). Male patients showed a positive correlation between final height and target genetic height (P <0.05). No difference was found in final height between patients diagnosed in the prepubertal or pubertal phase (173.6 ± 3.5 cm vs. 172.7 ± 5.5 cm; P-value n.s.). No correlation was found between final height and age at onset, duration of disease, insulin requirement, or degree of metabolic control. Taking into account all patients, diabetes did not influence final height, which was higher than target genetic height. Only in 5 out of 37 patients with poor metabolic control was the final height lower than target genetic height.

KW - Final height

KW - Growth

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=0027931127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027931127&partnerID=8YFLogxK

U2 - 10.1016/0168-8227(94)90115-5

DO - 10.1016/0168-8227(94)90115-5

M3 - Article

C2 - 7988351

AN - SCOPUS:0027931127

VL - 24

SP - 187

EP - 193

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

IS - 3

ER -